Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Not applicableStudy completedNCT06534424
What this trial is testing

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Who this might be right for
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Ohio State University Comprehensive Cancer Center 152
Not applicableLooking for participantsNCT04494945
What this trial is testing

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Who this might be right for
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeBreast Ductal Carcinoma In SituHematopoietic and Lymphoid System Neoplasm+3 more
OHSU Knight Cancer Institute 27,500
Testing effectiveness (Phase 2)Ended earlyNCT02203513
What this trial is testing

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Ovarian CancerBreast CancerProstate Cancer
National Cancer Institute (NCI) 111